Acasti Pharma Share Holder Equity 2014-2023 | ACST
Acasti Pharma share holder equity from 2014 to 2023. Share holder equity can be defined as the sum of preferred and common equity items
Acasti Pharma Annual Share Holder Equity
(Millions of US $) |
| 2023 |
$68 |
| 2022 |
$108 |
| 2021 |
$56 |
| 2020 |
$13 |
| 2019 |
$11 |
| 2018 |
$6 |
| 2017 |
$17 |
| 2016 |
$21 |
| 2015 |
$21 |
| 2015 |
$ |
| 2014 |
$32 |
| 2014 |
$ |
| 2013 |
$10 |
| 2013 |
$ |
Acasti Pharma Quarterly Share Holder Equity
(Millions of US $) |
| 2023-12-31 |
$65 |
| 2023-09-30 |
$67 |
| 2023-06-30 |
$64 |
| 2023-03-31 |
$68 |
| 2022-12-31 |
$97 |
| 2022-09-30 |
$100 |
| 2022-06-30 |
$104 |
| 2022-03-31 |
$108 |
| 2021-12-31 |
$111 |
| 2021-09-30 |
$114 |
| 2021-06-30 |
$53 |
| 2021-03-31 |
$56 |
| 2020-12-31 |
$26 |
| 2020-09-30 |
$9 |
| 2020-06-30 |
$11 |
| 2020-03-31 |
$13 |
| 2019-12-31 |
$-5 |
| 2019-09-30 |
$-1 |
| 2019-06-30 |
$3 |
| 2019-03-31 |
$11 |
| 2018-12-31 |
$23 |
| 2018-09-30 |
$-11 |
| 2018-06-30 |
$6 |
| 2018-03-31 |
$6 |
| 2017-12-31 |
$12 |
| 2017-09-30 |
$12 |
| 2017-06-30 |
$14 |
| 2017-02-28 |
$17 |
| 2016-11-30 |
$15 |
| 2016-08-31 |
$17 |
| 2016-05-31 |
$19 |
| 2016-03-31 |
$19 |
| 2016-02-29 |
|
| 2015-12-31 |
$22 |
| 2015-09-30 |
$24 |
| 2015-06-30 |
$26 |
| 2015-03-31 |
$30 |
| 2014-12-31 |
$32 |
| 2014-09-30 |
$30 |
| 2014-06-30 |
$32 |
| 2014-03-31 |
$32 |
| 2014-02-28 |
|
| 2013-12-31 |
$20 |
| 2013-09-30 |
$21 |
| 2013-06-30 |
$8 |
| 2013-03-31 |
$10 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.027B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
